12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vosaroxin: Phase III ongoing

Sunesis said an independent DSMB recommended continuation of the double-blind, international Phase III VALOR trial based on a safety review. The trial, which has enrolled 168 of a planned 450 patients, is comparing IV vosaroxin plus cytarabine vs. placebo plus cytarabine. The next DSMB review of...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >